The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
A toxicologist’s viewpoint on developing oncology drug products
Webinar On Demand
With oncology growth rates on the rise, pharma companies are pressured to develop and manufacture life-saving therapies with speed and agility. Cancer growth rates are driven by environmental factors, lifestyle choices, and an aging population. Approximately 42% of the oncology market pipeline is attributed to oral solid doses*. Since oncology drugs are commonly categorized as highly potent, they require various handling and safety strategies. Attend this webinar to hear toxicologist, Joe Galati, discuss:
- Criteria for evaluating highly potent small molecules
- Toxicity binding systems
- Downgrading a molecule from high potent to low potent:
- Safety and handling strategies
*Source: IQVIA- Global MIDAS Edition Includes antineoplastic agents (L01) and endocrine therapy (L02)- 248 molecules, OSD includes: tablets, ODT, capsules
Joe Galati
Senior Director of Global Toxicology Services, Thermo Fisher Scientific
Bio: Dr. Joe Galati is the Senior Director of Global Toxicology Services and has 20 years of experience in the pharmaceutical industry, in the field of occupational toxicology and patient/product safety. Involved in evaluating the toxicity of compounds (active pharmaceutical ingredients, intermediates, contaminants, etc.) in order to assign appropriate toxicity categorizations/bands, determine low potency versus high potency, and develop occupational exposure limits for worker safety, as well as threshold of toxicological concern/permitted daily exposure/acceptable daily exposure values for patient safety. Also involved in identifying whether the handling of compounds complies with the requirements for Good Manufacturing Practice in a multi-product facility and advising on potential drug product quality/regulatory concerns, such as cytotoxic, cytostatic, hormone, sensitizer, and others. A full member of the U.S. Society of Toxicology, as well as the Society of Toxicology of Canada, with a Ph.D. in Pharmacology and Molecular Toxicology from the University of Toronto. Also, an author of several peer-reviewed publications, and a presenter at various international scientific meetings, conferences, and universities, in North America and Europe.
